Automated algorithms to characterize myocardial optical coherence tomography imaging
Despite risks of complication and suboptimal diagnostic yield, endomyocardial biopsy (EMB), an invasive procedure in which a piece of heart tissue is extracted and analyzed, remains the gold standard for diagnosing unexplained myocardial disease. Currently, EMB is performed by randomly sampling myocardial tissue. This tissue is then examined under a microscope for diagnosis. The diagnostic yield of the procedure is low because a relatively small area of the heart is sampled. Alternatively, increasing the number of samples increases cardiac scarring, which is also undesirable. This technology describes a non-invasive method of imaging over large areas of the heart that can be used to provide more information than EMB alone. This technology could be used by research laboratories and academic institutions to improve the detection of heart transplant rejection and cardiomyopathies, as well as provide information regarding the outcomes of treatment decisions and new therapy options.
Decreases the number of tissue samples requiredIncreases the diagnostic yield of tissue samplingAllows clinician to avoid biopsy of important structuresTech Ventures Reference: IR CU14291
Cardiac tissue samplingMonitoring atherosclerotic and hypertrophic cardiovascular changesMonitoring heart transplant rejection
None
美國
